A Prospective Comparative Study of a Novel Gadolinium-Weighted MRI Sequence Versus Conventional T1-Weighted Imaging for the Detection of Brain Metastases

What this Trial Is About

Researchers are evaluating a new MRI technique called a gadolinium-weighted sequence to improve the detection of brain metastases in patients undergoing brain scans. The study aims to find out if this novel MRI method can identify more or smaller tumors compared to the standard T1-weighted imaging currently used. The goal is to enhance diagnostic accuracy without increasing the contrast dose or scan time. Participants will have a routine brain MRI with gadolinium contrast, followed by an additional scan using the new gadolinium-weighted MRI sequence during the same session. This new sequence includes advanced features to reduce background signals and better highlight tumors. Both imaging methods will be compared in the same exam to assess their ability to detect brain metastases. During the study, participants will undergo the combined MRI session lasting up to an hour after contrast injection. Researchers will measure the difference in the number of detected brain tumors between the two imaging sequences. The study involves patients known or suspected to have brain metastases and will monitor their ability to lie still during the exam and provide consent. The overall participation involves one MRI visit with no additional contrast or extended scan time.

Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison